Related pages Drug Information Summaries Approval Process for New Cancer Treatments Access to Investigational Drugs: Q & A

This page contains brief information about ixabepilone and a collection of links to more information from the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the National Library of Medicine (NLM).

US Brand Name(s):		Ixempra
FDA Approved:		Yes

Ixabepilone is approved by the Food and Drug Administration (FDA) to be used alone or together with a drug called capecitabine to treat metastatic or locally advanced breast cancer. It is used in patients who have not gotten better with other chemotherapy.

Ixabepilone is also being studied in the treatment of other types of cancer.

FDA Approval for Ixabepilone - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

New Chemotherapy Agents Travel Winding Road (09/25/2007) - Information about the use of this drug to treat cancer.

MedlinePlus Information on Ixabepilone - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Clinical Trials for Ixabepilone - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.

Back to Top